CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Adagio (ADGI) plummets as treatment ineffective against Omicron

By Andrew Knoll

23:37, 14 December 2021

A rendering of the Covid-19 virus
Adagio stock went into a tailspin Tuesday on negative clinical trials results - Photo: Unsplash

Adagio Therapeutics (ADGI) plunged nearly 79% to an all-time low of $7.26 on Wednesday following its release of clinical trial results demonstrating that its ADG20 antibody therapy was not effective in neutralising the Omicron variant.

On 29 November, Adagio had touted the potential effectiveness of the experimental antibody therapy. That news release spurred an 86% spike in the price of its stock. The notion posited by CEO Tillman Gerngross was that the antibody would likely bind to the structure of the Omicron variant as it would earlier iterations of the Covid-19 virus, so as not to diminish its efficacy in neutralising the virus. In vitro analyses, however, contradicted that hypothesis.

“We anticipated that ADG20 would retain neutralising activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern,” Gerngross wrote. “While the individual mutations present in the Omicron receptor binding domain were not associated with escape from ADG20 in the context of an original strain of the virus, new data show that the combination of mutations present in the Omicron spike protein led to a reduction in ADG20 neutralisation that was not suggested by prior data.”

What’s next?

Adagio said that it was pausing patient recruitment at its sites in South Africa and that it was currently evaluating future plans for ADG20. Another antibody treatment in its pipeline, ADG10, “showed minimal neutralising activity against the Omicron variant in both authentic and pseudovirus neutralisation assays,” Adagio said.

Adagio is a biotech company dedicated to advancing treatment options against Covid, but thus far it has not yielded any approved drugs or other therapies. It spawned off the privately-owned Adimab last July.

Adagio went public in August and gross proceeds from the IPO approached $356m (£269M). Such a significant setback could pose a difficult-to-surmount threat to investor confidence.


0.63 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040


2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30


Given the scale of the pandemic and its consequences, established, diversified biotech entities like Pfizer and GlaxoSmithKline have been joined by some new, Covid-specific actors in the sector like Adagio.

Some companies have as many as 18 related treatments and vaccines in development, led by Sorrento Therapeutics (18) and Canada-based ImmunoPrecise Antibodies (10).

Both the latter companies have strengthened relationships in order to advance the development of preventive and interventive Covid-related products, but neither has seen it lead to a significant boost for its investors. 

Read more:

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading